Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.

Plastic wound protectors reduce infection rate after laparoscope-assisted colectomy

01 Oct 2017
Laparoscopy surgery in action

Plastic wound protectors, applied to the extraction incision, can reduce postoperative wound infection rates in laparoscope-assisted colectomy, a new cohort study has shown.

There were 109 colorectal cancer patients (median age 58.61±1.12 years) included in the study, all of whom underwent laparoscopic-assisted colectomy. Patients with severe cardiac and pulmonary dysfunction, insufficient bowel preparation, anaemia and diabetes were excluded.

Of the patients, those who received the wound protector (n=57) had significantly shorter postoperative hospital stay than those who did not receive the protector (n=52; 8.73±0.54 vs 7.47±0.24 days; p=0.03). The two groups were comparable in terms of operative time (p=0.37), blood loss (p=0.43) and postoperative exhaust time (p=0.15).

Wound infection rates were significantly lower in patients who received the wound protector than in those who did not (1.75 vs 13.46 percent; p=0.02). Adhesive intestinal obstruction (5.26 percent; n=3) and uroschesis (3.51 percent; n=2) were the most common infections in the wound protector group.

In contrast, wound infection was the most common complication in the nonwound protector group. This was followed by adhesive intestinal obstruction (5.77 percent; n=3) and uroschesis (3.85 percent; n=2). There were no significant differences between the two groups in the rates of other complications.

Surgical site infections are the most common types of complications in laparoscopic-assisted surgery and are known to play a substantial role in patient morbidity and mortality. In colorectal cancer surgery, infectious agents most often come from the skin or gastrointestinal tract.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Cathy Chow, PhD, 27 Aug 2015

HER2-positive breast cancer tends to be more aggressive, has worse patient prognosis, and responds less to treatment. A two-pronged approach to block the HER pathway via pertuzumab (Perjeta®, Roche), a first-in-class HER dimerization inhibitor, in combination with trastuzumab and chemotherapy, may offer more treatment options for HER2-positive metastatic breast cancer patients as well as those with early breast cancer. 

Saras Ramiya, 25 Oct 2017
The first patient-reported outcomes study on durvalumab treatment after chemoradiation in locally advanced non-small cell lung cancer (NSCLC) shows patients’ quality of life is similar to that of the patients who received placebo.
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.